182 related articles for article (PubMed ID: 32739394)
1. Novel iron oxide nanocarriers loading finasteride or dutasteride: Enhanced skin penetration for topical treatment of alopecia.
Afiune LAF; Ushirobira CY; Barbosa DPP; de Souza PEN; Leles MIG; Cunha-Filho M; Gelfuso GM; Soler MAG; Gratieri T
Int J Pharm; 2020 Sep; 587():119709. PubMed ID: 32739394
[TBL] [Abstract][Full Text] [Related]
2. Finasteride Topical Delivery Systems for Androgenetic Alopecia.
Khan MZU; Khan SA; Ubaid M; Shah A; Kousar R; Murtaza G
Curr Drug Deliv; 2018; 15(8):1100-1111. PubMed ID: 29366416
[TBL] [Abstract][Full Text] [Related]
3. Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: A randomized controlled open-label, evaluator-blinded study.
Shanshanwal SJ; Dhurat RS
Indian J Dermatol Venereol Leprol; 2017; 83(1):47-54. PubMed ID: 27549867
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the therapeutic effects of AGA drugs by measuring finasteride, dutasteride, and dihydrotestosterone in hair.
Hobo Y; Nishikawa J; Taniguchi Asai N; Yoneyama K; Watanabe Y; Miyashiro Y; Fujikata A
Clin Chim Acta; 2023 Jul; 547():117456. PubMed ID: 37385468
[TBL] [Abstract][Full Text] [Related]
5. Dutasteride nanoemulsion preparation to inhibit 5-alpha-hair follicle reductase enzymes in the hair follicle; an ex vivo study.
Memar Bashi Aval M; Hoveizi E; Mombeiny R; Kazemi M; Saeedi S; Tavakol S
IET Nanobiotechnol; 2023 Feb; 17(1):13-21. PubMed ID: 36314605
[TBL] [Abstract][Full Text] [Related]
6. The effectiveness of finasteride and dutasteride used for 3 years in women with androgenetic alopecia.
Boersma IH; Oranje AP; Grimalt R; Iorizzo M; Piraccini BM; Verdonschot EH
Indian J Dermatol Venereol Leprol; 2014; 80(6):521-5. PubMed ID: 25382509
[TBL] [Abstract][Full Text] [Related]
7. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.
Gubelin Harcha W; Barboza Martínez J; Tsai TF; Katsuoka K; Kawashima M; Tsuboi R; Barnes A; Ferron-Brady G; Chetty D
J Am Acad Dermatol; 2014 Mar; 70(3):489-498.e3. PubMed ID: 24411083
[TBL] [Abstract][Full Text] [Related]
8. Change in Prostate Specific Antigen Concentration in Men with Prostate Specific Antigen Less than 2.5 ng/ml Taking Low Dose Finasteride or Dutasteride for Male Androgenetic Alopecia.
Kang HW; Chae MH; Park SH; Seo SP; Kim WT; Kim YJ; Yun SJ; Lee SC; Yoon TY; Kim WJ
J Urol; 2017 Dec; 198(6):1340-1345. PubMed ID: 28743526
[TBL] [Abstract][Full Text] [Related]
9. Dutasteride in Androgenetic Alopecia: An Update.
Arif T; Dorjay K; Adil M; Sami M
Curr Clin Pharmacol; 2017; 12(1):31-35. PubMed ID: 28294070
[TBL] [Abstract][Full Text] [Related]
10. Finasteride and Its Potential for the Treatment of Female Pattern Hair Loss: Evidence to Date.
Iamsumang W; Leerunyakul K; Suchonwanit P
Drug Des Devel Ther; 2020; 14():951-959. PubMed ID: 32184564
[TBL] [Abstract][Full Text] [Related]
11. Design of Finasteride-Loaded Nanoparticles for Potential Treatment of Alopecia.
Roque LV; Dias IS; Cruz N; Rebelo A; Roberto A; Rijo P; Reis CP
Skin Pharmacol Physiol; 2017; 30(4):197-204. PubMed ID: 28689207
[TBL] [Abstract][Full Text] [Related]
12. Lipid nanoparticles for topical and transdermal application for alopecia treatment: development, physicochemical characterization, and in vitro release and penetration studies.
Gomes MJ; Martins S; Ferreira D; Segundo MA; Reis S
Int J Nanomedicine; 2014; 9():1231-42. PubMed ID: 24634584
[TBL] [Abstract][Full Text] [Related]
13. The efficacy and safety of 5α-reductase inhibitors in androgenetic alopecia: a network meta-analysis and benefit-risk assessment of finasteride and dutasteride.
Gupta AK; Charrette A
J Dermatolog Treat; 2014 Apr; 25(2):156-61. PubMed ID: 23768246
[TBL] [Abstract][Full Text] [Related]
14. Development and Evaluation of Dutasteride Nanoemulgel for the Topical Delivery against Androgenic Alopecia.
Alam M; Mishra A; Yadav KS; Pradhan D; Kar B; Ghosh G; Rath G; Rai VK
Pharm Nanotechnol; 2024 Jan; ():. PubMed ID: 38173065
[TBL] [Abstract][Full Text] [Related]
15. Enhanced skin penetration of Finasteride loaded DMSO-liposomes for the treatment of androgenic alopecia: comparison with conventional liposomes.
Ramkar S; Kaurav M; Sudheesh MS; Pandey RS
Drug Dev Ind Pharm; 2023 Jan; 49(1):52-61. PubMed ID: 36803490
[TBL] [Abstract][Full Text] [Related]
16. Adverse Sexual Effects of Treatment with Finasteride or Dutasteride for Male Androgenetic Alopecia: A Systematic Review and Meta-analysis.
Lee S; Lee YB; Choe SJ; Lee WS
Acta Derm Venereol; 2019 Jan; 99(1):12-17. PubMed ID: 30206635
[TBL] [Abstract][Full Text] [Related]
17. Androgenetic alopecia; drug safety and therapeutic strategies.
Motofei IG; Rowland DL; Baconi DL; Tampa M; Sârbu MI; Păunică S; Constantin VD; Bălălău C; Păunică I; Georgescu SR
Expert Opin Drug Saf; 2018 Apr; 17(4):407-412. PubMed ID: 29363345
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy with finasteride and low-dose dutasteride in the treatment of androgenetic alopecia.
Boyapati A; Sinclair R
Australas J Dermatol; 2013 Feb; 54(1):49-51. PubMed ID: 22686691
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of non-surgical treatments for androgenetic alopecia: a systematic review and network meta-analysis.
Gupta AK; Mays RR; Dotzert MS; Versteeg SG; Shear NH; Piguet V
J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2112-2125. PubMed ID: 29797431
[TBL] [Abstract][Full Text] [Related]
20. 5-Alpha reductase inhibitors in androgenetic alopecia: Shifting paradigms, current concepts, comparative efficacy, and safety.
Dhurat R; Sharma A; Rudnicka L; Kroumpouzos G; Kassir M; Galadari H; Wollina U; Lotti T; Golubovic M; Binic I; Grabbe S; Goldust M
Dermatol Ther; 2020 May; 33(3):e13379. PubMed ID: 32279398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
